Drugs / Bacillus Calmette-Guérin
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00023842 | Jun 2001 → Feb 2005 | urinary bladder cancer | European Organisation for Research and Treatment of Cancer - EORTC | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bacillus Calmette-Guérin | “Bacillus Calmette-Guérin (BCG) is the intravesical treatment of choice for carcinoma in situ (CIS).” PMID 21156335 ↗ Dec 2010 |
| Known as | BCG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00023842 ↗ |
| Modality | Vaccine | “BCG vaccine” NCT00023842 ↗ |
| Route | Other | “intravesical BCG” NCT00023842 ↗ |